Clincosm LogoSign in Get a demo

ALPH: Serum Cholinesterase Level in Aluminum Phosphide Poisoning, the Possible Proposing Role of Atropin & Pralidoxime

Sponsor
Assiut University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04192526
Collaborator
(none)
50
Enrollment
1
Location
8
Anticipated Duration (Months)
6.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Metal phosphides are widely used as a rodenticide and insecticide and poisoning with these substances has a very high mortality. The aim of this study was to evaluate the butyrylcholinesterase (BuCh) level in poisoning with metal phosphides.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Today, the use of pesticides in the world is considered as a recognized health It is estimated that around 30% of global suicides are due to pesticide self-poisoning . Metal phosphides pesticides are highly toxic, low cost, and are easily accessible as rodenticide agents and used for self-poisoning . aluminum phosphide (ALP) are among the most important metal phosphides. Poisoning with these agents is frequently seen in India, Srilanka and Iran. In a recent study, the incidence of fatal aluminum phosphide poisoning cases referred for phosphine analysis was 5.22 and 37.02 per million of population of Tehran, Iran in 2006 and 2013, respectively (9).The mechanism of toxicity is not clearly defined. ALP toxicity is related to the production of phosphine gas. Phosphine inhibits cytochrome c oxidase and causes mitochondrial destruction and inhibits oxidative respiration which leads to anaerobic metabolism, severe metabolic acidosis, multi-organ dysfunction and death. Phosphine can lead to severe cardiac suppression and cardiogenic shock. One of the proposed mechanisms of toxicity is the reduction of the true cholinesterase and serum cholinesterase (butyrylcholinesterase) enzyme, but usually do not show obvious clinical manifestations .

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    50 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Assessment of Serum Cholinesrtrase Level in Aluminum Phosphide Poisoning Cases, the Possible Proposing Role of Atropine and Pralidoxime in Saving the Cases: Clinical and
    Actual Study Start Date :
    Dec 1, 2019
    Actual Primary Completion Date :
    Apr 30, 2020
    Anticipated Study Completion Date :
    Jul 30, 2020

    Outcome Measures

    Primary Outcome Measures

    1. persistent cholineastrase inhibition is one of the pathological pathway of the ALP poisoning [3 months]

      definite assessment of the pathogenesis of ALP helps in applying adaquqte treatment regmin

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria: cases of aluminum phosphide poisoning -

    Exclusion Criteria: concomitant ingestion

    -

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 AssiutU Assiut Egypt

    Sponsors and Collaborators

    • Assiut University

    Investigators

    • Principal Investigator: Doaa Abd el rahman, AssiutU, faculty of medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Doaa Mohamed Abd El-Rahman, lecture, Assiut University
    ClinicalTrials.gov Identifier:
    NCT04192526
    Other Study ID Numbers:
    • serum cholinestrase in AP
    First Posted:
    Dec 10, 2019
    Last Update Posted:
    May 13, 2020
    Last Verified:
    May 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Doaa Mohamed Abd El-Rahman, lecture, Assiut University
    serum cholinestrase, atropin, aluminum phosphide
    Additional relevant MeSH terms:
    Poisoning

    Study Results

    No Results Posted as of May 13, 2020